BACKGROUND: The aim of the current study was to investigate the role of BRCA1 promoter methylation as predictive factor of response to platinum-taxane-based therapy in sporadic ovarian cancer. PATIENTS AND METHODS: BRCA1 promoter methylation was analyzed in 42 sporadic epithelial ovarian cancers. The results were validated in a second cohort of 137 ovarian cancer patients. RESULTS: BRCA1 promoter methylation was observed in 35.7 % of patients in the first group and in 33.6 % in the second group. BRCA1 promoter methylation was associated with significant increase in median progression-free survival (PFS) of ovarian cancer patients receiving adjuvant platinum-taxane-based chemotherapy (P = 0.008). Multivariate analysis revealed that BRCA1 promoter methylation remains a favorable factor in regard to PFS (HR 0.52; 95 % CI 0.32-0.85, P = 0.009) after adjustment for other prognostic factors. Under the patients with recurrent disease, BRCA1 promoter methylation was associated with significant longer median PFS of 18.5 months in comparison with 12.8 months PFS for patients without BRCA1 promoter methylation. CONCLUSIONS: BRCA1 promoter methylation is predictive for better response to platinum-taxane-based therapy in EOC.
BACKGROUND: The aim of the current study was to investigate the role of BRCA1 promoter methylation as predictive factor of response to platinum-taxane-based therapy in sporadic ovarian cancer. PATIENTS AND METHODS: BRCA1 promoter methylation was analyzed in 42 sporadic epithelial ovarian cancers. The results were validated in a second cohort of 137 ovarian cancerpatients. RESULTS:BRCA1 promoter methylation was observed in 35.7 % of patients in the first group and in 33.6 % in the second group. BRCA1 promoter methylation was associated with significant increase in median progression-free survival (PFS) of ovarian cancerpatients receiving adjuvant platinum-taxane-based chemotherapy (P = 0.008). Multivariate analysis revealed that BRCA1 promoter methylation remains a favorable factor in regard to PFS (HR 0.52; 95 % CI 0.32-0.85, P = 0.009) after adjustment for other prognostic factors. Under the patients with recurrent disease, BRCA1 promoter methylation was associated with significant longer median PFS of 18.5 months in comparison with 12.8 months PFS for patients without BRCA1 promoter methylation. CONCLUSIONS:BRCA1 promoter methylation is predictive for better response to platinum-taxane-based therapy in EOC.
Authors: Philipp Harter; Felix Hilpert; Sven Mahner; Florian Heitz; Jacobus Pfisterer; Andreas du Bois Journal: Expert Rev Anticancer Ther Date: 2010-01 Impact factor: 4.512
Authors: J Boyd; Y Sonoda; M G Federici; F Bogomolniy; E Rhei; D L Maresco; P E Saigo; L A Almadrones; R R Barakat; C L Brown; D S Chi; J P Curtin; E A Poynor; W J Hoskins Journal: JAMA Date: 2000-05-03 Impact factor: 56.272
Authors: Richard E Buller; Mark S Shahin; John P Geisler; Melanie Zogg; Barry R De Young; Charles S Davis Journal: Clin Cancer Res Date: 2002-05 Impact factor: 12.531
Authors: K P M Suijkerbuijk; M J Fackler; S Sukumar; C H van Gils; T van Laar; E van der Wall; M Vooijs; P J van Diest Journal: Ann Oncol Date: 2008-07-22 Impact factor: 32.976
Authors: Elizabeth M Swisher; Rachel M Gonzalez; Toshiyasu Taniguchi; Rochelle L Garcia; Tom Walsh; Barbara A Goff; Piri Welcsh Journal: Mol Cancer Date: 2009-07-14 Impact factor: 27.401
Authors: Roshni D Kalachand; Britta Stordal; Stephen Madden; Benjamin Chandler; Julie Cunningham; Ellen L Goode; Ilary Ruscito; Elena I Braicu; Jalid Sehouli; Atanas Ignatov; Herbert Yu; Dionyssios Katsaros; Gordon B Mills; Karen H Lu; Mark S Carey; Kirsten M Timms; Jolanta Kupryjanczyk; Iwona K Rzepecka; Agnieszka Podgorska; Jessica N McAlpine; Elizabeth M Swisher; Sarah S Bernards; Ciaran O'Riain; Sharon O'Toole; John J O'Leary; David D Bowtell; David M Thomas; Katharina Prieske; Simon A Joosse; Linn Woelber; Parvesh Chaudhry; Norman Häfner; Ingo B Runnebaum; Bryan T Hennessy Journal: J Natl Cancer Inst Date: 2020-12-14 Impact factor: 13.506
Authors: Arun Kanakkanthara; Catherine J Huntoon; Xiaonan Hou; Minzhi Zhang; Ethan P Heinzen; Daniel R O'Brien; Ann L Oberg; S John Weroha; Scott H Kaufmann; Larry M Karnitz Journal: Nat Commun Date: 2019-10-11 Impact factor: 14.919
Authors: Katharina Prieske; Stefan Prieske; Simon A Joosse; Fabian Trillsch; Donata Grimm; Eike Burandt; Sven Mahner; Barbara Schmalfeldt; Karin Milde-Langosch; Leticia Oliveira-Ferrer; Linn Woelber Journal: Oncotarget Date: 2017-09-15